Vicore Pharma Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ahmed Mousa

Chief executive officer

SEK 6.3m

Total compensation

CEO salary percentage	23.5%
CEO tenure	1.4yrs
CEO ownership	n/a
Management average tenure	2yrs
Board average tenure	1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ahmed Mousa's remuneration changed compared to Vicore Pharma Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 6m	SEK 1m	-SEK 311m

Compensation vs Market: Ahmed's total compensation ($USD598.20K) is about average for companies of similar size in the German market ($USD778.79K).

Compensation vs Earnings: Insufficient data to compare Ahmed's compensation with company performance.

CEO

Ahmed Mousa (39 yo)

1.4yrs

Tenure

SEK 6,339,074

Compensation

Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ahmed Mousa	Chief Executive Officer	1.4yrs	SEK 6.34m	no data
Hans Jeppsson	Chief Financial Officer	7yrs	no data	0.0045% SEK 9.4k
Mikael Nygård	Vice President of Operations & Corporate Strategy	less than a year	no data	0.0036% SEK 7.6k
Johan Raud	Chief Scientific Officer	6.4yrs	no data	0.21% SEK 450.5k
Nina Carlen	Chief Administrative Officer	15.4yrs	no data	0.022% SEK 46.2k
Jessica Shull	Head of Digital Therapeutics & Director of Digital Health	3.1yrs	no data	no data
Asa Magnusson	Chief Engagement & Commercial Officer	2.7yrs	no data	no data
Bertil Lindmark	Chief Medical Officer	less than a year	no data	no data
Sophie Bertilsson	Interim Head of CMC	less than a year	no data	no data
Jimmie Hofman	Vice President of Business Development	less than a year	no data	no data

2.0yrs

Average Tenure

58yo

Average Age

Experienced Management: 6Y4's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jacob Gunterberg	Director	no data	SEK 886.00k	0.0057% SEK 12.1k
Michael Buschle	Director	1.1yrs	SEK 405.00k	no data
Ann Barbier	Director	less than a year	no data	no data
Yasir Al-Wakeel	Director	less than a year	no data	no data
Hans J. G. C. Schikan	Independent Chairman	5.8yrs	SEK 450.00k	0.0036% SEK 7.5k
Elisabeth Bjork	Director	1.1yrs	SEK 405.00k	no data
Heidi Hunter	Independent Director	4.1yrs	SEK 519.00k	0.0045% SEK 9.4k

1.1yrs

Average Tenure

63yo

Average Age

Experienced Board: 6Y4's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Vicore Pharma Holding Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Recent updates

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

New 90-day high: €2.82

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: €1.78

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021

Vicore Pharma Holding AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Vicore Pharma Holding AB (Publ) Announces Completion of Patient Enrollment in the Covid-19 Attract Trial

Vicore Pharma Holding AB (publ) Announces Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age